menu
    • menu

    Company profile for TG Therapeutics

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found ...
    TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing umbralisib (TGR-1202), an oral, once-daily inhibitor of PI3K-delta.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    TG TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2 Gansevoort Street, 9th Floor New York, NY 10014
    Telephone
    Telephone
    212.554.4484
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.tgtherapeutics.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/tg-therapeutics
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/tgtherapeutics?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    TG Therapeutics To Attend Evercore Healthcare Conference
    TG Therapeutics To Attend Evercore Healthcare Conference

    28 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/28/3196225/8790/en/TG-Therapeutics-to-Participate-in-the-8th-Annual-Evercore-Healthcare-Conference.html

    GLOBENEWSWIRE
    28 Nov 2025
    Share Share
    TG Therapeutics Enters 2025 Deloitte Fast 500 List
    TG Therapeutics Enters 2025 Deloitte Fast 500 List

    19 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/19/3190944/8790/en/TG-Therapeutics-Makes-2025-Deloitte-Technology-Fast-500-List-of-America-s-Fastest-Growing-Companies.html

    GLOBENEWSWIRE
    19 Nov 2025
    Share Share
    TG Therapeutics Joins TD Cowen Immunology & Inflammation Summit
    TG Therapeutics Joins TD Cowen Immunology & Inflammation Summit

    10 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/10/3185016/8790/en/TG-Therapeutics-to-Participate-in-the-TD-Cowen-Immunology-Inflammation-Summit.html

    GLOBENEWSWIRE
    10 Nov 2025
    Share Share
    TG Therapeutics To Host Q3 2025 Financial Results Conference Call
    TG Therapeutics To Host Q3 2025 Financial Results Conference Call

    31 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/31/3178245/8790/en/TG-Therapeutics-to-Host-Conference-Call-on-Third-Quarter-2025-Financial-Results-and-Business-Update.html

    GLOBENEWSWIRE
    31 Oct 2025
    Share Share
    TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial
    TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial

    28 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/28/3175281/8790/en/TG-Therapeutics-Completes-Enrollment-in-the-Phase-3-ENHANCE-Trial-Evaluating-its-New-Simplified-Dosing-Schedule-for-BRIUMVI.html

    GLOBENEWSWIRE
    28 Oct 2025
    Share Share
    Ublituximab Ms Data To Debut At Ectrims 2025 With Tg Therapeutics
    Ublituximab Ms Data To Debut At Ectrims 2025 With Tg Therapeutics

    23 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-23/new-ublituximab-data-in-multiple-sclerosis-to-be-presented-at-ectrims-congress-2025-alongside-partner-tg-therapeutics

    PHARMAWEB
    23 Sep 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search